Dr Jorge Mestre-Ferrandiz, OHE's Director of Consulting, was a recent guest lecturer at Imperial College London. His comprehensive presentation covered the gamut of issues that influence the rate and direction of R&D for medicines, including regulatory approval requirements, the patent system, the economics of R&D, the roles of the public and private sectors, “push” and “pull” incentives, and the influence of capital markets.
In this video, Adrian Towse discusses the challenges and importance of appropriately valuing genomic medicine. He addresses both gene therapies and “pharmacogenomics” -- those medicines that will allow targeted, precision treatment.
Advances in science and technology are producing more and better means for diagnosing disease, matching patients to the best therapies, and tracking the progress of treatment. The potential impact of using diagnostic and therapeutic tests in tandem with treatment—“co-dependent technologies”—potentially can maximise both treatment effectiveness and economic efficiency.
OHE’s Dr Jorge Mestre-Ferrandiz is a visiting lecturer in the Department of Economics at City University London. As part of his 2013 activities, he recently gave a comprehensive lecture on the economics of the market for medicines in the UK. His presentation covers the key issues, from drug development through health technology assessment and market access.
OHE's Jorge Mestre-Ferrandiz reviewed the results of OHE's recent study on the R&D cost of developing a new drug at a seminar at University College London. Released in December 2012, the study's purpose was to capture and examine in one place the important research on the cost of drug development that had been published over the past 30 years.
How much it costs to research and develop a successful new medicine has been an important policy issue at least since the 1960s. Cost estimates matter not just because of intellectual curiosity or for industry understanding of its performance, but because they are a key aspect of the international debate about the reasonableness of pharmaceutical prices and the magnitude of the long-term investments involved. The Office of Health Economics today released a comprehensive study of the cost of R&D for new medicines.
One of the greatest challenges in biomedical and health research is ensuring that research findings are translated effectively and without undue delay from ‘bench to bedside’. As previous analysis has made clear, the time that elapses between discoveries in medical research and adoption in practice is important. Longer time lags mean a lower rate of return on the research investment, which makes it less attractive to do the research in the first place.
OHE has just published a Seminar Briefing by Ulf Persson, head of the Swedish Institute of Health Economics, which reviews experience with the Swedish value based pricing (VBP) system. Prof Persson is a member of the board of the TLV, which is the health technology assessment (HTA) agency in Sweden.
OHE’s health and health care statistics service long has been respected as a source of reliable data. In an OHE Briefing just published, OHE uses this data to take a closer look at what has been responsible for changes in the causes of death in England and Wales.
In this OHE lunchtime seminar, Prof Heidi Williams of MIT will present the results of a recent paper using newly-collected data on the sequencing of the human genome by the public Human Genome Project and the private firm Celera to investigate how Celera's gene-level IP influenced subsequent scientific research and product development.